HK1253737A1 - 在ctdna中具有pik3ca突变的预选患者中用pi3k抑制剂治疗癌症 - Google Patents

在ctdna中具有pik3ca突变的预选患者中用pi3k抑制剂治疗癌症 Download PDF

Info

Publication number
HK1253737A1
HK1253737A1 HK18112889.9A HK18112889A HK1253737A1 HK 1253737 A1 HK1253737 A1 HK 1253737A1 HK 18112889 A HK18112889 A HK 18112889A HK 1253737 A1 HK1253737 A1 HK 1253737A1
Authority
HK
Hong Kong
Prior art keywords
cancer
patient
ctdna
preselected
treatment
Prior art date
Application number
HK18112889.9A
Other languages
English (en)
Chinese (zh)
Inventor
Emmanuelle DI TOMASO
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1253737A1 publication Critical patent/HK1253737A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK18112889.9A 2015-12-03 2016-11-30 在ctdna中具有pik3ca突变的预选患者中用pi3k抑制剂治疗癌症 HK1253737A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562262620P 2015-12-03 2015-12-03
US62/262,620 2015-12-03

Publications (1)

Publication Number Publication Date
HK1253737A1 true HK1253737A1 (zh) 2019-06-28

Family

ID=57517943

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18112889.9A HK1253737A1 (zh) 2015-12-03 2016-11-30 在ctdna中具有pik3ca突变的预选患者中用pi3k抑制剂治疗癌症

Country Status (13)

Country Link
US (2) US20180353515A1 (cg-RX-API-DMAC7.html)
EP (1) EP3383391A1 (cg-RX-API-DMAC7.html)
JP (1) JP2018535997A (cg-RX-API-DMAC7.html)
KR (1) KR20180084830A (cg-RX-API-DMAC7.html)
CN (1) CN108366998A (cg-RX-API-DMAC7.html)
AU (1) AU2016362683B2 (cg-RX-API-DMAC7.html)
CA (1) CA3006419A1 (cg-RX-API-DMAC7.html)
HK (1) HK1253737A1 (cg-RX-API-DMAC7.html)
IL (1) IL259716A (cg-RX-API-DMAC7.html)
MX (1) MX2018006777A (cg-RX-API-DMAC7.html)
RU (1) RU2018123524A (cg-RX-API-DMAC7.html)
TW (1) TW201722429A (cg-RX-API-DMAC7.html)
WO (1) WO2017093905A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020081549A1 (en) * 2018-10-15 2020-04-23 The Regents Of The University Of California Methods and materials for assessing and treating cancer
CN116240287A (zh) * 2023-01-17 2023-06-09 普洱市人民医院 基于循环肿瘤dna的乳腺癌标志物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048627B2 (en) 2003-07-05 2011-11-01 The Johns Hopkins University Method and compositions for detection and enumeration of genetic variations
ES2537633T3 (es) 2004-03-02 2015-06-10 The Johns Hopkins University Mutaciones del gen de PIK3CA en cánceres humanos
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
BRPI0816769A2 (pt) 2007-09-12 2016-11-29 Hoffmann La Roche combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso
WO2009055730A1 (en) 2007-10-25 2009-04-30 Genentech, Inc. Process for making thienopyrimidine compounds
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US20130317037A1 (en) * 2010-11-16 2013-11-28 Glaxosmithkline Intellectual Property Development Limited Method of administration and treatment
EP2830621B1 (en) * 2012-03-29 2020-10-21 Novartis AG Pharmaceutical diagnostic
EP3140427B1 (en) * 2014-05-09 2020-10-14 Memorial Sloan Kettering Cancer Center Biomarkers for response to pi3k inhibitors

Also Published As

Publication number Publication date
RU2018123524A3 (cg-RX-API-DMAC7.html) 2020-04-02
TW201722429A (zh) 2017-07-01
MX2018006777A (es) 2018-08-01
AU2016362683B2 (en) 2019-11-07
US20200138824A1 (en) 2020-05-07
US20180353515A1 (en) 2018-12-13
KR20180084830A (ko) 2018-07-25
RU2018123524A (ru) 2020-01-09
CN108366998A (zh) 2018-08-03
WO2017093905A1 (en) 2017-06-08
CA3006419A1 (en) 2017-06-08
AU2016362683A1 (en) 2018-05-31
IL259716A (en) 2018-07-31
EP3383391A1 (en) 2018-10-10
JP2018535997A (ja) 2018-12-06

Similar Documents

Publication Publication Date Title
WO2015172085A3 (en) Biomarkers for response to pi3k inhibitors
EP4733325A3 (en) Multi-specific wnt surrogate molecules and uses thereof
EA201890512A1 (ru) Способы лечения пациентов со злокачественными опухолями с использованием ингибиторов фарнезилтрансферазы
WO2017066136A3 (en) Antibody agents specific for human cd19 and uses thereof
CY1116728T1 (el) Παραγοντες οι οποιοι επαγουν αποπτωση για την αντιμετωπιση καρκινου και ανοσολογικων και αυτοανοσων νοσηματων
WO2016141324A3 (en) Early assessment of mechanism of action and efficacy of anti-cancer therapies using molecular markers in bodily fluids
WO2017093804A3 (en) Materials and methods for treatment of alpha-1 antitrypsin deficiency
EA201890428A1 (ru) Ингибиторы контрольных точек иммунного ответа для применения в лечении различных видов рака крови
WO2015191777A3 (en) Devices and methods for collecting and stabilizing biological samples
EP3761034A3 (en) Urine biomarkers for prediction of recovery after acute kidney injury: proteomics
EA033286B1 (ru) Способ лечения или отсрочки развития хронической болезни почек
WO2013010136A3 (en) Inhibitors of bruton's tyrosine kinase
EA201792182A1 (ru) Композиции и способы для лечения анемии
MX2014002471A (es) Combinaciones sinergicas de los inhibidores de p13k y mek.
MX2015017629A (es) Combinaciones farmaceuticas.
BR112017022323A2 (pt) método para tratar doença do enxerto contra hospedeiro, uso de um composto, e, kit.
WO2018031490A3 (en) Anti-ox40 binding proteins
EP4585273A3 (en) Mechanism of resistance to bet bromodomain inhibitors
NZ703225A (en) Superior efficacy of cd37 antibodies in cll blood samples
EP4279128A3 (en) Novel antibody binding to tfpi and composition comprising the same
EA201790563A8 (ru) Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой
EP3765476C0 (en) MODIFIED OLIGONUCLEOTIDES FOR USE IN THE TREATMENT OF TAUOPATHIES
HK1259083A1 (zh) 用於治疗系统性肥大细胞增多症的方法和组合物
MX2015017058A (es) Combinaciones farmaceuticas de un inhibidor de pi3k y un agente de desestabilizacion de microtubulos.
HK1200723A1 (en) Pharmaceutical diagnostic